The prognosis and prediction of adjuvant chemotherapy (ACT) response in early-stage non-small cell lung cancer (NSCLC) patients remain poor in this era of personalized medicine. We hypothesize that extracellular matrix (ECM)-associated components could be potential markers for better diagnosis and prognosis due to their differential expression in 1,943 primary NSCLC tumors as compared to 303 normal lung tissues. Here we develop a 29-gene ECM-related prognostic and predictive indicator (EPPI). We validate a robust performance of the EPPI risk scoring system in multiple independent data sets, comprising a total of 2,071 early-stage NSCLC tumors. Patients are stratified according to the universal cutoff score based on the EPPI when applied in the clinical setting; the low-risk group has significantly better survival outcome. The functional EPPI gene set represents a potential genomic tool to improve patient selection in early-stage NSCLC to further derive the best benefits of ACT and prevent unnecessary treatment or ACT-associated morbidity.
Tumor stage is currently the best-established prognostic factor of patient survival1. Aside from this stage classification, much effort has been devoted to determine single oncogenes or biomarkers. In particular, recent successes in oncogene-directed therapies have improved patient survival2. For example, Oncotype DX testing (Genomic Health Inc, Redwood City, CA) has allowed improved prediction of recurrence risk and allocation of chemotherapy to patients who would most likely to benefit in breast cancer3. In contrast, lung cancer has seen few medical advances. A 5-year survival remains at 50–60% for stage I, 30−40% for stage II, and 15–20% for stage III lung cancer4. In particular, non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related fatalities5. Although advanced or metastatic (late-stage) NSCLC has routine testing for targets such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements, there is still lack of validated genetic risk stratification score to select patients who may best benefit from adjuvant chemotherapy (ACT) among early-stage resected NSCLC patients4. Adjuvant studies that randomized EGFR mutant lung cancer to adjuvant EGFR tyrosine kinase inhibitors or chemotherapy have also demonstrated no survival benefits6. Immense efforts in uncovering potential multigene assays for molecular prognostic tests have recently resulted in two genetic tests being marketed as Pervenio Lung RS (Life Technologies, West Sacramento, CA, USA) and myPlan Lung Cancer (Myriad Genetics, Inc., Salt Lake City, UT, USA). Although both assays have been validated in some patient cohorts7,8 using formalin-fixed and paraffin-embedded (FFPE) specimens, the success of a prospective randomized clinical trial is still warranted for their immediate clinical utility.
Bidirectional crosstalk between tumor cells and their surrounding stroma is critical in tumor growth and progression9. Whereas cancer has been previously examined for genetic or epigenetic mutations in epithelial cells, it is now clear that the extracellular cues in tumor microenvironment (TME) also regulate cancer development and metastasis10. The extracellular matrix (ECM) components, in particular, have been perceived as important regulators in cancer progression11. Stromal and epithelial cells in cancer microenvironment jointly disrupt them and their dynamics has become a hallmark of cancer12. Abnormal ECM, such as disrupted organization and changes in essential composition or topography of the ECM, has been implicated in cancer initiation and metastasis by remodeling the behavior of stromal cells and promoting tumor-associated angiogenesis and inflammation11. Hence, understanding how tumor-derived ECM components manifest in the diseased state may help identify new prognostic or therapeutic targets.
Here, our developed bioinformatics pipeline for large scale meta-analysis revealed differential expressions and significant enrichment of ECM-associated components in 1,943 primary NSCLC tumors relative to 303 normal lung tissues. We thus hypothesized that ECM genes play a significant role in predicting metastasis, recurrence risk and survival. A 29-gene ECM-related prognostic and predictive indicator (EPPI)13 was specifically constructed and its robust performance was validated in multiple independent data sets comprising 2,071 early-stage NSCLC patients. To facilitate its clinical utility, the universal cutoff EPPI risk score, which stratifies patients with better overall survival (OS) was identified. This was further validated in identifying patients who would benefit from ACT in an independent validation cohort.
Construction of a 29-gene EPPI related to NSCLC
The bioinformatics workflow of our integrative genomic analysis is illustrated in Fig. 1. Batch effects arising from 10 independent microarray data sets were successfully adjusted as validated using principal components analysis (PCA). The first two principal components of the ComBat-transformed data (discovery set) which capture the most variance are shown in Fig. 2a. The PCA plot of samples adjusted for batch effect showed a clear separation between 925 primary NSCLC tumors and 193 normal lung tissue samples (Fig. 2b). We identified a total of 103 differentially expressed genes (DEG) that met our stringent statistical threshold in NSCLC compared to normal phenotype (Supplementary Table 1). Figure 2c shows a volcano plot revealing 32 upregulated and 71 downregulated genes in NSCLC. To dispel the existing bias against feature selection methods based on ranking genes, the overlap between DEG lists derived from random sampling was computed for 10,000 iterations (Fig. 2d). We took smaller subsets randomly from the discovery set and applied the same statistical criteria used to define the DEG list. The mean of the overlap coefficients computed for the iterations (mean overlap coefficient = 0.899) suggests there is significant overlap using the discovery set comprising 1,118 samples.
Since the DEGs used to construct the EPPI were identified from merged microarray data sets, we further validated the 103 DEGs in an independent cohort comprising RNA-Seq transcriptional profiling of 1,018 primary NSCLC tumors and 110 normal lung tissues from lung adenocarcinoma and squamous cell carcinoma patients (Fig. 2e). The estimates of log 2 fold changes of gene expression values between the samples across the two different platforms were highly correlated as shown in Fig. 2f (Spearman correlation = 0.914, P < 2.2e-16). Gene set enrichment analysis (GSEA)-generated results further showed significant enrichment scores for both upregulated (ES = 0.929, P < 0.001) and downregulated gene set (ES = −0.904, P < 0.001) in the diseased phenotype compared to normal tissues in the RNA-Seq platform (Fig. 2g).
Interestingly, gene ontology enrichment analysis of the 103 DEGs identified ECM-associated molecules, comprising 28% of the DEGs (n = 29), to be the most differentially enriched cellular components in the diseased state (Fig. 2h). We hypothesized that these identified ECM components play a significant role in the molecular pathways associated with NSCLC malignancy and their gene expression patterns may collectively predict clinical outcomes. Using three gene ontology databases, we constructed the EPPI gene set comprising the 29 ECM-related genes that were identified to be differentially expressed in primary NSCLC tumors (Supplementary Table 2).
Personalized EPPI risk scoring system for patient classification
We systematically analyzed the patient groups in the discovery data set to develop the EPPI based risk scoring system. Patients without complete survival information or at late-stage NSCLC were excluded in the univariate Cox regression analysis. Altogether, 489 early-stage NSCLC patients from the initial discovery set were included to generate the Cox regression coefficient of each EPPI gene (Supplementary Table 3). The EPPI risk score of each patient in the discovery set was then computed using the regression coefficient and represented collectively in the EPPI gene expression heatmap in Fig. 3a. The data are sorted in increasing EPPI risk scores and each patient’s survival status is depicted as well. Forest plots illustrating the hazard ratios (HRs) and 95% confidence intervals (CIs) for each EPPI gene are presented with its respective Cox regression coefficient (Fig. 3b).
Time-dependent area under a receiver operating characteristic (ROC) curve (AUC) analyses were further performed in order to compare the prognostic performance of different patient classification methods. The AUC analyses for a 10-year survival demonstrated better performance of the EPPI risk scoring system compared to an unsupervised hierarchical clustering technique in classifying patients with different survival outcomes (Fig. 3c). The prognostic performance of different cutoff score was also compared in the AUC analyses to determine the best cutoff computation method. An optimal cutoff score, defined as the EPPI risk score with the most significant split using log-rank test, was selected to demonstrate the prognostic performance of the 29 EPPI genes in multiple independent data sets.
Robust prognostic performance in early-stage tumors
The ability of the 29-gene EPPI signature in stratifying early-stage NSCLC tumors with different prognosis was confirmed in multiple validation cohorts comprising a total of 2071 early-stage NSCLC patients. Only stage IA to IIB patients with complete demographic information were included and patients were censored at their last examination, or at 10 years follow-up in all validation runs. The histology profiles of the samples included two studies comprising exclusively of lung adenocarcinomas (GSE68465, TCGA), and one of squamous cell carcinoma (GSE4573), and six of mixed histological types (GSE3141, GSE37745, GSE30219, GSE42127, GSE41271, and GSE11969). Patients annotated with ACT were excluded from the survival analyses.
Unsupervised hierarchical clustering of each validation cohort was first performed to demonstrate a robust prognostic performance of the EPPI gene signature in classifying patients with different survival outcomes (Supplementary Fig. 1). As demonstrated by consistently high HRs across validation cohorts, there was a significant association between survival and EPPI gene panel. We further tested the potential of the clinical utility of our developed EPPI risk scoring system in stratifying patients. The optimal cutoff value was determined for each cohort to divide early-stage patients into two classes, designated as low-risk and high-risk groups. Remarkably, the 29-gene EPPI was closely associated with OS in all validation cohorts (Fig. 4a). The predicted high-risk group had statistically significant shorter OS compared with those in the low-risk group as shown in univariate Cox regression analyses.
All validation cohorts demonstrated significant log-rank P-value (P < 0.05) despite the absence of few EPPI genes in some microarray platforms, demonstrating the strong prognostic performance of the EPPI gene signature in early-stage NSCLC patients. We also tested the association between the EPPI and RFS in the data sets using RFS as an endpoint (GSE50081 and GSE31210 from the discovery set, and GSE68465; Fig. 4b). The predicted high-risk group consistently had worse RFS outcomes than the low-risk group as shown in Fig. 4b.
Since only data sets with almost complete demographic information were evaluated, we further conducted multivariate Cox regression survival analyses to adjust for other clinical variables such as histology (ADC: adenocarcinoma; LCC: large cell carcinoma; SCC: squamous cell carcinoma), sex, smoking history, AJCC tumor staging (Stage IA−IIB) and age. Importantly, multivariate survival analyses showed that the EPPI signature remains to be an independent indicator of survival outcomes after the adjustment (Table 1). We further directly compared our model to these clinicopathological factors that are known to be associated with survival to some extent (Supplementary Fig. 3). Despite significant p-values for tumor staging, age and histology in few data sets, our gene signature has the strongest prognostic performance in most data sets (8 out of 10 validation cohorts). Although EPPI model also shows statistically significance in the other two data sets, histology and tumor staging shows better performance in GSE30219 and TCGA, respectively. Nevertheless, our gene panel remains to be the most significant factor compared to five clinicopathological factors in majority of early-stage NSCLC patients.
Gene clusters generated from hierarchical clustering using validation cohorts probed with the full-gene platforms (Discovery set, GSE3141, GSE37745, and GSE30219) revealed that high-risk groups associated with worse survival displayed consistently elevated expressions of collagens (COL10A1, COL11A1), matrix metallopeptidases (MMP1, MMP12), secreted factors (S100A2), glycoproteins (CTHRC1, SPP1), and ECM-affiliated proteins, or genes encoding proteins affiliated structurally or functionally to ECM proteins (GREM1) and low expressions of surfactant proteins (SFTPC, SFTPA2, SFTPD), secreted proteins (CHRDL1, WIFI), ECM-regulated genes (CPB2, MAMDC2, HHIP, LPL, CD36, ADAMTS8), collagen (COL6A6), ECM-affiliated proteins (FCN3), ECM glycoproteins (TNNC1, ABI3BP), and proteoglycan (OGN). Using the patient demographic information, we further compared how patients designated into different risk group differ in terms of other clinical variables (Fig. 4c). The high-risk group consisted of patients with a slightly higher proportion of men, patients with squamous cell carcinoma, patients with smoking history, and stage II patients compared to low-risk group.
The universal EPPI cutoff score for patient stratification
To evaluate the clinical application of the EPPI risk score, we performed AUC analyses to determine a universal threshold that can be applied to all early-stage NSCLC patients. As different microarray platforms measure the same gene with varying expression levels on different scales and ranges14, the most commonly available platform in a public repository of gene expression profiles was chosen to assess the potential of defining a universal EPPI risk score. The common cutoff value was determined as the median of the optimal cutoff scores at 5-year and 10-year survival, identified from the time-dependent AUC analyses using the discovery set, as shown in Fig. 5a (cutoff score = 20.8). The cutoff was applied to stratify patients into low-risk and high-risk group in multiple independent data sets that were probed with the same platform (Fig. 5b). Figure 5c shows that the common threshold separated patients into groups with significantly different survival outcomes in both discovery and validation cohorts.
Prediction of the adjuvant chemotherapy response
We further tested the therapeutic predictive utility of the EPPI signature in an independent validation cohort, hypothesizing that the high-risk group would likely benefit from the ACT: 144 tumors from GSE42127 comprising 35 patients who received ACT and 109 patients who did not receive ACT. We systematically compared the predictive performance of our EPPI scoring system with known clinical prognostic markers using ROC/AUC analyses. The tested clinical variables included AJCC staging, histology, and gender. In order to assess the predictive accuracy of these models, time-dependent AUC analyses for 10-year survival were compared (Fig. 6a). The data suggest that the EPPI risk score has a best prognostic accuracy in predicting survival post surgery. With estimation of sensitivity and specificity using ROC curves, the optimal cutoff score was further determined to assign patients into different groups and identify those who may benefit from ACT (cutoff score = 21.7; Fig. 6b). Patients were ranked by their EPPI risk score and separated into low-risk and high-risk groups with the optimal cutoff score (Fig. 6c). Figure 6d shows that the OBS cohort experienced shorter survival than those with ACT in the high-risk group whereas patients who received ACT had no significant survival benefits relative to those without ACT in the low-risk group.
Although numerous gene panels have been claimed to be prognostic for early-stage NSCLC tumors (Supplementary Table 5), EPPI gene panel comprising specific ECM molecules has critical biological and clinical significance. As opposed to these existing signatures where genes were first ranked and selected solely based on their prognostic power using prior information of known survival outcomes, we were completely blinded to survival data when drawing EPPI signature; only existing biological knowledge was used for gene selection, particularly for biological motives representing ECM matrix that links tumor cells and surrounding enzymes in tumor microenvironment using multiple gene ontology databases. For this, we found it remarkable that early-stage tumors of a particular kind of lung cancer, NSCLC, can be stratified with different prognosis based on ECM molecules alone, considering their highly variable and dynamic properties15. The diverse expression levels shown in each patient further suggests inter-tumor heterogeneity in relation to ECM components in the tumor microenvironment.
Potential involvement of these 29 specific ECM molecules in resistance to therapeutic intervention further highlights the significance of downstream analysis of ECM mediated signaling pathways in identifying druggable targets against NSCLC tumors. This finding is significant not just in demonstrating predictive value for prognosis but also in uncovering gene signature for the prioritization of tumor microenvironment-targeting therapeutic approaches. Despite immense efforts, designing rational therapy targeting cancer-associated fibroblasts (CAFs), for example, has been challenged and resulted in significant toxicity due to lack of definitive biomarkers in distinguishing ‘activated’ CAFs from normal fibroblasts16. Such lack of specificity and prior knowledge of tumor microenvironment at the molecular level truly necessitates specific ECM biomarkers to develop more precise and less toxic targeted therapies for medical utility. In this regard, our gene panel holds great promise in providing novel potential targets for stroma-directed therapeutic approaches—in fact, one of our ECM component, COL11A1, has very recently been reported as a highly specific biomarker of activated CAFs together with other co-expressed genes, which has further validated in 13 different types of cancers in TCGA data16.
We have thoroughly revisited gene panels from 61 studies that have been previously claimed to be prognostically important (Supplementary Table 5). For fair comparison to our ECM gene panel, signatures selected based on biological motives were included for schematic demonstration (Supplementary Fig. 2). Here, only three factors that are considered to be most significant in developing clinically applicable multigene assay in a routine clinical setting are shown: (1). Hazard ratios for stratifying performance; (2). Validation sample size for statistical robustness; and (3). Number of genes used in the panel for feasibility and practicality. Some of these signatures with biological implications include cancer-related genes such as TOP2A 8,17,18, PI3K-related genes17, and VEGFA 19, which are known to be significantly associated with clinopathological factors20,21. Even when comparing to these signatures, our ECM gene panel demonstrates comparable and even stronger prognostic performance in greater number of validation cohorts (Supplementary Fig. 2). Nevertheless, as Subramanian et al.22 critically pointed out, hazard ratio is not sufficient enough to demonstrate predictive power; thus ROC curves were further obtained to demonstrate that EPPI risk score is a statistically better predictor of survival than known standard risk factors, including AJCC staging, histology, smoking status and gender, which were often missed in prior studies.
The differences observed in terms of traditional clinical factors between the low-risk and high-risk groups may exert undue bias, as shown from previously published studies23. In order to account for these clinical parameters, we performed multivariate Cox regression independently for each validation cohort adjusting for each clinical prognostic indicator to compute if these variables had any influence in assessing the predictive value of the EPPI. Consistently, the EPPI was shown to be the best prognostic factor among all the established clinical variables and remained to have statistical significance in predicting survival of early-stage NSCLC patients (Table 1). Direct comparison to traditional clinicopathological factors was further done and our EPPI gene panel again remains to be better predictor of survival than known risk factors in most validation cohorts (Supplementary Fig. 3).
As our gene panel involves a minimal number of genes that can be quantified for its expression in a standard way using RT-PCR, genetic assays can be directly applied to FFPE specimens, which are usually available after surgical resection, for prospectively conducted validation study. In fact, Pervenio Lung RS and myPlan Lung Cancer have been tested with FFPE samples to derive risk score and demonstrated the feasibility of using FFPE tumor blocks or consecutive slides with defined criteria for tumor size and density24. In situations where samples have incomplete EPPI expression data, we have demonstrated that the clinical utility remains strong. Nevertheless, it is noteworthy that the use of the entire gene set is favored.
The developed genomic algorithm greatly reduced the computational complexity of the integrative genomic analysis. The stringent statistical criteria for differential expression analysis applied in this study narrowed down more than 20,000 genes to statistically significant and stable genes that may significantly contribute to cancer-associated molecular pathways, particularly in ECM remodeling. Interestingly, subsets of the genes in the EPPI had been previously reported for their differential expression in lung cancer or even other lung diseases such as idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF) when compared with normal lung tissues (Supplementary Table 4; Fig. 7a). The EPPI and previously identified differentially expressed genes from published transcriptome analysis of diseased lung tissues for IPF patients, in particular, demonstrate significant overlapping gene expression patterns. Among them, three genes, SPP1, MMP1, and S100A2, were strikingly upregulated and four genes, FCN3, HHIP, S100A12, and CPB2, were downregulated in both NSCLC and IPF. We thus speculate that the patterns of the EPPI gene expression might be a critical gauge for impaired lung function, and 29 genes in the EPPI might form a network and collectively mediate tumor initiation. The EPPI signature may further be associated with the underlying mechanism of carcinogenesis such as epithelial-mesenchymal transition (EMT) or mesenchymal-epithelial transition (MET). For example, in vivo development of the alveolar epithelial EMT was found to be regulated by the ECM components during IPF25. It could therefore be valuable to investigate the association of each EPPI signature with the initiation of EMT, which may explain the fundamentals of tumor initiation.
Individual components of the EPPI have also been confirmed to have strong predictive value in other cancer types. Particularly, two genes of the EPPI gene signature, namely SPP1 and OGN, which encodes ECM glycoprotein and proteoglycan, respectively, were identified among 26 stromal gene signatures that stratified disease outcome in primary breast tumors12. Consistent with these findings, 79 differentially expressed genes identified in another study26 between primary breast cancers and paired lymph node metastases further overlapped with four genes from the EPPI: COL11A1, CTHRC1, PCOLCE2, and OGN. These differentially expressed genes were found to predict tumors with high risk of developing metastasis within 43 months, establishing their potential prognostic value in predicting clinical outcome of node-positive patients. Beyond the shared expression patterns of the EPPI gene signature in other lung diseases, the potential prognostic performance in other types of cancer further provide the possible association of cancer progression to be related to ECM-dependent molecular pathways.
Prior assessment of primary breast carcinomas and matching lymph node metastases27 revealed ECM molecules, comprising 18% of differentially expressed genes, to be most differentially enriched. Additionally, a recent single-cell RNA-seq study28 found unexpected high abundance of ECM transcripts in substantial proportion of enriched circulating tumor cells (CTCs), which were shed from matched primary pancreatic tumors into the bloodstream. The knockdown of one of highly expressed ECM proteins in cancer cells, SPARC, suppressed cell migration and invasion, suggesting the potential role of CTCs in the classical “seed” carrying their own “soil” to metastasize28. Most interestingly, four genes of our EPPI overlapped with their differentially expressed genes in CTCs vs. matched primary pancreatic tumors: SPP1, ABI3BP, OGN, and SFTPD. While this study has demonstrated potential benefits of applying the EPPI as a selection tool for ACT in patients at high risk of relapse, this further remains to be validated in larger subsets of patients or in a prospectively conducted study.
One of the limitations of this study is the small sample size used to predict the survival benefits of ACT using the EPPI risk score. This is due to the incomplete demographic information in the many available public data sets. We therefore plan to assess the EPPI signature in a larger validation data set cohort. This will aid to establish the cutoff value over a wider range of patient subtypes. Another limitation is the cross platform compatibility of our EPPI risk scoring matrix, as other platforms use different scale range and have varying gene expression values. Nevertheless, we established our work using the most widely adopted platforms, demonstrating its successful classifications of early-stage patients. In our attempt to meet the criteria set by Subramanian et al.22 for a clinically applicable gene expression-based prognostic signature, we have thoroughly revisited and analyzed our findings again and believe that the EPPI gene panel fulfill most of the stated standards (Fig. 7b). This shows the promising results for its clinical application and our informatics analyses can be easily translated to other platforms as well.
Although our current universal cutoff score was determined at the intersection point of sensitivity and specificity, this score may not always be the most optimal point in the clinical practice; we believe that achieving higher sensitivity is more critical (even at the expense of having low specificity; that is producing a higher proportion of false-positive results) as treatment and survival outcomes greatly depends on the stage of cancer at diagnosis in NSCLC. If patients are put at considerable risk by receiving false-positive results, it may be reasonable to compromise sensitivity—in which we believe is less significant than identifying more patients with early-stage cancer for greater benefits. Taken together, our study demonstrated a critical and important analysis technique that will complement current disease management. With potential role of ECM proteins in cancer progression highlighted, we believe understanding the role of specific EPPI gene molecules in metastasis may further provide potential targets for future intervention and therapy. A prospective randomized clinical interventional study based on the EPPI signature will better confirm our analysis to maximize the benefit of the treatment administered to patients.
Transcriptional profiles and clinical annotations were downloaded from the National Center for Biotechnology Information Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo) via the inSilicoDb package29 in R/Bioconductor. In order to minimize undesired variations from different platforms, only samples probed with Affymetrix Human Genome U133 Plus 2.0 (HG-U133_Plus_2) Array were selected as the discovery set. Manual curation was done to include only primary NSCLC tumors such as adenocarcinoma, squamous cell carcinoma (SCC), and large cell carcinoma (LCC) and normal lung tissues. Ten primary NSCLC tumor data sets (Fig. 2a) from the GEO repository were downloaded, pre-processed and normalized using frozen Robust Multi-array Average (fRMA).
Since combining multiple data sets into one large-scale analysis carry over non-biological experimental variations or batch-effects30, direct adjustment for the undesired batch effects with the Empirical Bayes algorithm implemented in ComBat was performed in these fRMA-normalized NSCLC data sets using the inSilicoMerging package31. Principal Component Analysis (PCA) was carried out using the prcomp function to collapse high-dimensional data into the first two components and they were visualized using via the ggbiplot package32 in order to validate the batch-effect removal in Combat-transformed data. A total cohort of 1118 human samples including 925 primary NSCLC tumors and 193 normal lung epithelial tissues were generated for the identification of differentially expressed genes. The genefilter package33 was subsequently used to apply a filter to remove genes with low variance across samples, improving the computational processing time by focusing only on statistically significant genes.
Construction of the EPPI signature
Differential expression was assessed by a linear regression method using the R/Bioconductor limma package34. We applied stringent statistical cutoffs of log2FC > 1.5 and adjusted p-value < 1.0E-10 for genes to be determined as differentially expressed in the integrated primary NSCLC tumor data for subsequent discovery and analysis. Volcano plot was generated using the ggplot2 package35 to graphically reveal genes that differ significantly between two phenotypes of diseased and normal samples. Limma-generated differentially expressed genes that met our statistical criteria were filtered to construct the ECM-related gene list using the Matrisome database36, Gene Ontology (GO) Consortium13 and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database37. A descriptive list of 29 EPPI genes including the fold change (log2-base) and adjusted p-value (false discovery rate) is shown in Supplementary Table 2.
Level-3 RNAseqV2 gene expression profiles were downloaded from the Cancer Genome Atlas (TCGA) using the TCGA-Assembler package38. The data comprised clinical information and gene expression values of 1018 primary tumors and 110 normal lung tissues from patients with adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC). The raw data were processed with RNA-Seq by expectancy maximization (RSEM), and genes without least zero RSEM count in at least 20% of the samples were removed for further differential expression analysis. Differential expression analysis was performed using the voom function in the limma package, with normalization by Trimmed Mean of M-values (TMM) via the edgeR package39.
Gene set enrichment analysis
The enrichment of identified upregulated and downregulated gene set identified using the discovery set was assessed in TCGA cohorts using GSEA v2.2.2. GSEA computes the enrichment score by applying weighted Kolmogorov−Smirnov statistic to a running sum of the ranked list with 1000 permutations. The enrichment score (ES) was further normalized to account for the size of each inputted gene set. The false discovery rates (FDR) <0.001 were assumed to be statistically significant.
EPPI classifier validation and its prognostic evaluation
To validate the prognostic value of the EPPI in predicting OS and RFS, normalized gene expression profiles (log2 transformed) from eight independent microarray data sets across four different platforms of Affymetrix (HG-U133A and HG-U133_Plus_2), Illumina (HumanWG-6 v3.0 Expression), and Agilent (014850 Whole Human Genome Microarray 4 × 44K G4112F) were downloaded via the GEO repository directly. For all validation cohorts, manual curation was done to select only primary tumors resected from stage IA to IIB (early-stage) patients and the survival data were censored at 10 years follow-up post surgery. Using a Spearman rank correlation as a distance metric selection, an unsupervised hierarchical clustering algorithm was first performed to test the prognostic value of the EPPI signature in the validation cohort (Supplementary Fig. 1) using the Institute of Genomic Research MultiExperiment Viewer (TIGR MeV) version 10.2 software. The EPPI risk score of each patient was then computed and used to divide patients into low and high-risk group based on the optimal cutoff score identified in each data set. The optimal cutoff EPPI risk score, which is defined as the score with the most significant split using log-rank test, was determined using the Cutoff Finder algorithm40.
Personalized EPPI risk score and gene expression heat maps
The regression coefficient of each EPPI gene was derived from 489 early-stage NSCLC patients who had complete survival information from the initial discovery set. The EPPI risk score was calculated as a sum of multiplication of the expression level of each EPPI gene and its respective Cox regression coefficient identified from the discovery set (EPPI risk score = 29+∑ (expression level of gene) X (Cox regression coefficient)). Each Cox regression coefficient used for EPPI risk score computation is shown in Supplementary Table 3. A constant was added to ensure all scores are positive. The risk score generated for each patient in the discovery set was visualized with a personalized two-dimensional heatmap using Gene-E open software (Broad Institute).
Time-dependent ROC, AUC, and survival analyses
Time-dependent receiver operator characteristic (ROC) and area under the curve (AUC) were computed using the survivalROC package41 in R. OS and RFS time were computed from the date of surgery until death and relapse of last follow-up contact, respectively. For all survival analyses in this study, both univariate and multivariate Cox proportional hazards model and Kaplan−Meier (KM) survival curves were used via the survival package in R/Bioconductor42. Hazard ratios were adjusted for available clinical variables in each data set such as smoking status, gender, age at diagnosis, histology and tumor stage. The Cox proportional hazard assumption was checked by Schoenfeld test using cox.zph function in survival library42.
Data for all the bioinformatics analyses using open-source R packages have been described throughout the text and are available under accession codes GSE10245, GSE10445, GSE10799, GSE12667, GSE18842, GSE19188, GSE28571, GSE31210, GSE33356, GSE50081, GSE3141, GSE37745, GSE30219, GSE68465, GSE4573, GSE42127, GSE41271, and GSE11969 from the National Center for Biotechnology Information Gene Expression Omnibus (GEO). All the statistical analyses have been performed using open-source R packages and described in Methods section. All other data associated with this work are available in the Supplementary Information or from the corresponding author upon reasonable request.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Mountain, C. F. Staging classification of lung cancer. A critical evaluation. Clin. Chest Med. 23, 103–121 (2002).
Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).
Wolf, I. et al. Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients. Cancer 112, 731–736 (2008).
Gerber, D. E., Oxnard, G. R. & Govindan, R. ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer. Clin. Pharmacol. Ther. 97, 447–450 (2015).
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics. Cancer J. Clin. 65, 5–29 (2015).
Thatcher, N. et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366, 1527–1537 (2005).
Kratz, J. R. et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet 379, 823–832 (2012).
Wistuba, I. I. et al. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma. Clin. Cancer Res. 19, 6261–6271 (2013).
Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423–1437 (2013).
Allinen, M. et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6, 17–32 (2004).
Lu, P., Weaver, V. M. & Werb, Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 196, 395–406 (2012).
Finak, G. et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14, 518–527 (2008).
Harris, M. A. et al. The gene ontology (GO) database and informatics resource. Nucleic Acids Res. 32, D258–D261 (2004).
Tan, P. K. et al. Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res. 31, 5676–5684 (2003).
Frantz, C., Stewart, K. M. & Weaver, V. M. The extracellular matrix at a glance. J. Cell Sci. 123, 4195–4200 (2010).
Jia, D. et al. A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets. Cancer Lett. 382, 203–214 (2016).
Rajski, M., Saaf, A. & Buess, M. BMP2 response pattern in human lung fibroblasts predicts outcome in lung adenocarcinomas. BMC Med. Genom. 8, 16 (2015).
Bueno, R. et al. Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma. J. Thorac. Oncol. 10, 67–73 (2015).
Buffa, F. M., Harris, A. L., West, C. M. & Miller, C. J. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br. J. Cancer 102, 428–435 (2010).
Martins, S. F. et al. Clinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer. Cancer Genom. Proteom. 10, 55–67 (2013).
Sullivan, G. F. et al. The expression of drug resistance gene products during the progression of human prostate cancer. Clin. Cancer Res. 4, 1393–1403 (1998).
Subramanian, J. & Simon, R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J. Natl. Cancer Inst. 102, 464–474 (2010).
Ciuleanu, T. et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 13, 300–308 (2012).
Myriad Genetics, Inc. myPlanTM Specimen Instructions. Available at https://s3.amazonaws.com/myriad-web/myriadpro.com/publications/116262_MyPlanInstruc_proof.pdf.
Kim, K. K. et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl Acad. Sci. USA 103, 13180–13185 (2006).
Feng, Y. et al. Differentially expressed genes between primary cancer and paired lymph node metastases predict clinical outcome of node-positive breast cancer patients. Breast Cancer Res. Treat. 103, 319–329 (2007).
Weigelt, B. et al. No common denominator for breast cancer lymph node metastasis. Br. J. Cancer 93, 924–932 (2005).
Ting, D. T. et al. Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. Cell Rep. 8, 1905–1918 (2014).
Coletta, A. et al. InSilico DB genomic datasets hub: an efficient starting point for analyzing genome-wide studies in GenePattern, Integrative Genomics Viewer, and R/Bioconductor. Genome Biol. 13, R104 (2012).
Lazar, C. et al. Batch effect removal methods for microarray gene expression data integration: a survey. Brief Bioinform. 14, 469–490 (2013).
Taminau, J. et al. Unlocking the potential of publicly available microarray data using inSilicoDb and inSilicoMerging R/Bioconductor packages. BMC Bioinform. 13, 335 (2012).
Vu, V. Q. ggbiplot: a ggplot2 based biplot. R package (2011).
Gentleman, R., Carey, V., Huber, W. & Hahne, F. Genefilter: methods for filtering genes from microarray experiments. R package version 1 (2011).
Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
Wickham, H. ggplot2: Elegant Graphics for Data Analysis (Springer-Verlag, New York, 2009).
Naba, A. et al. The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol. Cell Proteom. 11, M111 014647 (2012).
Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30 (2000).
Zhu, Y., Qiu, P. & Ji, Y. TCGA-assembler: open-source software for retrieving and processing TCGA data. Nat. Method. 11, 599–600 (2014).
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).
Budczies, J. et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS ONE 7, e51862 (2012).
Heagerty, P. J. & Zheng, Y. Survival model predictive accuracy and ROC curves. Biometrics 61, 92–105 (2005).
Therneau, T. L. T. A package for survival analysis in S. R package version 1, (2013).
This work was conceived and carried out at the MechanoBioEngineering laboratory at the Department of Biomedical Engineering, National University of Singapore (NUS). We thank both present and former members of the MechanoBioEngineering lab for their support and assistance. S.B.L. acknowledges scholarship and support from NUS Graduate School for Integrative Sciences and Engineering (NGS). Support provided by the National Research Foundation, Prime Minister's Office, Singapore under its Research Centre of Excellence, Mechanobiology Institute at NUS is also acknowledged.
About this article
npj Precision Oncology (2019)
BMC Cancer (2018)